{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018794","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.688301+00:00","generated_at":"2026-06-15T12:35:18.440509+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax Q1 net loss $41.1M; on track for two pivotal readouts and NDA/BLA filings in 2023","bullets":["Net loss of $41.1M ($0.59/sh) vs $37.2M ($0.63/sh) YoY; cash $449M as of Mar 31, 2023.","Topline data from AGAVE-201 (axatilimab in cGVHD) expected mid-2023; BLA filing by end of 2023.","Topline data from AUGMENT-101 (revumenib in KMT2Ar acute leukemia) expected Q3 2023; NDA filing by end of 2023.","Alexander Nolte resigned as VP, CAO; CFO Keith Goldan appointed as Principal Accounting Officer.","Full-year 2023 R&D expense guidance reaffirmed at $160-175M; total op ex $225-240M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018794","json":"https://secwatch.observer/filing/0000950170-23-018794.json","markdown":"https://secwatch.observer/filing/0000950170-23-018794.md","text":"https://secwatch.observer/filing/0000950170-23-018794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/sndx-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:35:18.440509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98a8800e970fa61db612eddfc4fe724a99495720","claim":"Syndax Pharmaceuticals Inc reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, Syndax Pharmaceuticals, Inc. (the \" Company \") issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"390ab42be1","claim":"Alexander Nolte resigned as Vice President, Chief Accounting Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"Effective May 5, 2023, Alexander Nolte resigned from his positions as the Company’s Vice President, Chief Accounting Officer and its Principal Accounting Officer, in order to pursue another opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Vice President, Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"ce27d53f4e","claim":"Keith A. Goldan was appointed as Principal Accounting Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"The Company has appointed Keith A. Goldan, the Company’s Chief Financial Officer, Treasurer and its Principal Financial Officer, as its Principal Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023018794/0000950170-23-018794-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}